Background: Serogroup C meningococcal conjugate polysaccharide vaccines have been reported to induce significant serum IgG antibodies and immunologic memory in infants. Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local mucosal immune responses may play an important role in host defense against infection and carriage. We have investigated the mucosal IgA and IgG antibody responses to two meningococcal C conjugate vaccines in the saliva of healthy infants.

Methods: Specific salivary IgA and IgG antibodies to two meningococcal C polysaccharide conjugate vaccines (Menjugate from Chiron Corp., n = 46; and Meningitec from Wyeth Lederle, n = 54) were investigated by immunoassay in infants after parenteral vaccinations at the ages of 2, 3 and 4 months. Unstimulated saliva samples were collected immediately before the first immunization and 1 month after the third immunizations. Forty healthy infants receiving the same routine vaccines but no meningococcal C vaccine were recruited as controls.

Results: There were significant increases in meningococcal C polysaccharide-specific IgG antibody concentrations postvaccination compared with prevaccination concentrations in both vaccinated groups (both P < 0.001), but no change in the control group. There were no significant increases in specific IgA postvaccination geometric mean concentrations in either the vaccine or the control groups. The number of IgA positives postvaccination increased slightly in the Wyeth vaccine group vs. controls (P < 0.05).

Conclusions: Significant salivary IgG antibodies to meningococcal C polysaccharide were observed after parenteral immunization with two meningococcal C conjugate vaccines, whereas there was no significant increase in specific IgA antibody levels for these two vaccines.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006454-200203000-00010DOI Listing

Publication Analysis

Top Keywords

meningococcal conjugate
16
igg antibodies
12
conjugate vaccines
12
mucosal immune
8
immune responses
8
meningococcal
8
responses meningococcal
8
conjugate polysaccharide
8
polysaccharide vaccines
8
iga igg
8

Similar Publications

[Microplanning as a tool to strengthen the National Immunization Program in BrazilLa microplanificación como herramienta para fortalecer el Programa Nacional de Inmunizaciones en Brasil].

Rev Panam Salud Publica

December 2024

Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente Departamento de Doenças Imunopreveníveis Brasília (DF) Brasil Ministério da Saúde, Secretaria de Vigilância em Saúde e Ambiente, Departamento de Doenças Imunopreveníveis, Brasília (DF), Brasil.

Objective: To measure the variation in number of doses, vaccination coverage (VC) of administered vaccines, and number of municipalities that achieved the VC target in Brazil with the implementation of microplanning for high-quality vaccination activities (HQVA) and decentralized multivaccination actions.

Methods: This quasi-experimental study used data from the National Live Birth Information System, the National Immunization Program Information System, and the National Health Data Network. The number of doses of hepatitis A (HA), meningococcal conjugate-C, oral poliomyelitis, 10-valent pneumococcal, diphtheria-tetanus-pertussis (DTP), and measles-mumps-rubella (MMR) vaccines administered to children under 2 years of age in 2022 (pre-microplanning) and 2023 (post-microplanning) was estimated.

View Article and Find Full Text PDF

Immune persistence following primary vaccination with a single dose of meningococcal quadrivalent conjugate vaccines, MenACYW-TT/MCV4-CRM, at age 10-12 years was demonstrated. Most participants primed with MenACYW-TT and MCV4-CRM maintained seroprotective titers against all serogroups, suggesting continued protection. Priming with MenACYW-TT resulted in higher persistent titers for serogroups C, W, and Y than MCV4-CRM.

View Article and Find Full Text PDF

Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control.

View Article and Find Full Text PDF

Objectives: To gather perspectives on childhood vaccination and vaccine hesitancy, the Saint Louis County Department of Public Health (DPH) surveyed parents seeking nonmedical exemptions, conducted focus groups of school nurses, and interviewed pediatricians.

Methods: We distributed exemption forms and voluntary questionnaires to parents in St Louis County who were seeking nonmedical exemptions for their school-aged children at any DPH clinic from August 2019 through December 2022. We conducted and recorded four 75- to 90-minute focus groups of 11 school nurses in groups of 2 or 3 nurses in September 2022.

View Article and Find Full Text PDF

Multivalent meningococcal conjugate vaccines are a significant focus for the scientific community in light of the WHO's mission to defeat meningitidis by 2030. Well-known meningococcal vaccines such as MenAfriVac, Nimenrix, Menveo, and MenQuadfi are licensed in various parts of the world and have been successful. Recently, the World Health Organization (WHO) qualified MenFive (meningococcal A, C, Y, W, and X) conjugate vaccine, further enhancing the battery of vaccines against meningitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!